Aculys Pharma has acquired development and commercialization rights to Neurelis’s Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and Vietnam. Aculys, which launched in 2021, describes itself as “a biopharmaceutical company focused on the development and commercialization of innovations in the fields of neurology and psychiatry.”
Neurelis President and CEO Craig C. Chambliss commented, “In most parts of the world there is a high unmet need for people with epilepsy to have a convenient, reliable, nasally administered acute treatment for episodes of frequent seizure activity that can be used outside of the medical setting. We are very pleased to partner with Aculys to work towards bringing this innovative treatment to Japan and the Asia-Pacific region.”
Neurelis Chief Medical Officer Enrique Carrazana said, “The long-term clinical study of Valtoco covers 4,390 seizure events and provides supportive evidence of its safety, effectiveness and tolerability. Since the US Food and Drug Administration (FDA) approval of Valtoco in 2020, there have been 65 posters presented at national and international scientific meetings and 16 publications describing its safety and efficacy results in treating seizure clusters.”
In March 2021, Neurelis announced that it had raised $114 million for commercialization of Valtoco. The company also recently initiated a Phase 1/2a trial of the nasal spray in pediatric epilepsy patients aged 2-5.
Read the Neurelis press release.
